Literature DB >> 30467812

Computerized assessment of cognitive impairment among children undergoing radiation therapy for medulloblastoma.

Andrew M Heitzer1, Jason M Ashford1, Brian T Harel2, Adrian Schembri3, Michelle A Swain4, Joanna Wallace5, Kirsten K Ness6, Fang Wang7, Hui Zhang7, Thomas E Merchant8, Giles W Robinson9, Amar Gajjar9, Heather M Conklin10.   

Abstract

PURPOSE: Advantages to computerized cognitive assessment include increased precision of response time measurement and greater availability of alternate forms. Cogstate is a computerized cognitive battery developed to monitor attention, memory, and processing speed. Although the literature suggests the domains assessed by Cogstate are areas of deficit in children undergoing treatment for medulloblastoma, the validity of Cogstate in this population has not been previously investigated.
METHODS: Children participating in an ongoing prospective trial of risk-adapted therapy for newly diagnosed medulloblastoma (n = 73; mean age at baseline = 12.1 years) were administered Cogstate at baseline (after surgery, prior to adjuvant therapy) and 3 months later (6 weeks after completion of radiation therapy). Gold-standard neuropsychological measures of similar functions were administered at baseline.
RESULTS: Linear mixed models revealed performance within age expectations at baseline across Cogstate tasks. Following radiation therapy, there was a decline in performance on Cogstate measures of reaction time (Identification and One Back). Females exhibited slower reaction time on One Back and Detection tasks at baseline. Higher-dose radiation therapy and younger age were associated with greater declines in performance. Pearson correlations revealed small-to-moderate correlations between Cogstate reaction time and working memory tasks with well-validated neuropsychological measures.
CONCLUSIONS: Cogstate is sensitive to acute cognitive effects experienced by some children with medulloblastoma and demonstrates associations with clinical predictors established in the literature. Correlations with neuropsychological measures of similar constructs offer additional evidence of validity. The findings provide support for the utility of Cogstate in monitoring acute cognitive effects in pediatric cancer.

Entities:  

Keywords:  Brain tumor; Cogstate; Medulloblastoma; Neuropsychology; Pediatric

Mesh:

Year:  2018        PMID: 30467812      PMCID: PMC6344264          DOI: 10.1007/s11060-018-03046-2

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  31 in total

Review 1.  Neurocognitive dysfunction in survivors of childhood brain tumors.

Authors:  Nicole J Ullrich; Leanne Embry
Journal:  Semin Pediatr Neurol       Date:  2012-03       Impact factor: 1.636

2.  Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.

Authors:  Roger J Packer; Amar Gajjar; Gilbert Vezina; Lucy Rorke-Adams; Peter C Burger; Patricia L Robertson; Lisa Bayer; Deborah LaFond; Bernadine R Donahue; MaryAnne H Marymont; Karin Muraszko; James Langston; Richard Sposto
Journal:  J Clin Oncol       Date:  2006-09-01       Impact factor: 44.544

3.  Attention and memory functioning among pediatric patients with medulloblastoma.

Authors:  Cara B Reeves; Shawna L Palmer; Wilburn E Reddick; Thomas E Merchant; Gray M Buchanan; Amar Gajjar; Raymond K Mulhern
Journal:  J Pediatr Psychol       Date:  2005-03-23

4.  Intellectual and academic outcome following two chemotherapy regimens and radiotherapy for average-risk medulloblastoma: COG A9961.

Authors:  M Douglas Ris; Karin Walsh; Dana Wallace; F Daniel Armstrong; Emi Holmes; Amar Gajjar; Tianni Zhou; Roger J Packer
Journal:  Pediatr Blood Cancer       Date:  2013-02-26       Impact factor: 3.167

Review 5.  Clinical trials in pediatric neuro-oncology: what is missing and how we can improve.

Authors:  Lennox Byer; Cassie Kline; Sabine Mueller
Journal:  CNS Oncol       Date:  2016-09-12

Review 6.  Late neurocognitive sequelae in survivors of brain tumours in childhood.

Authors:  Raymond K Mulhern; Thomas E Merchant; Amar Gajjar; Wilburn E Reddick; Larry E Kun
Journal:  Lancet Oncol       Date:  2004-07       Impact factor: 41.316

Review 7.  Neurodevelopmental impact on children treated for medulloblastoma: a review and proposed conceptual model.

Authors:  Shawna L Palmer
Journal:  Dev Disabil Res Rev       Date:  2008

8.  Change in neurocognitive functioning after treatment with cranial radiation in childhood.

Authors:  Brenda J Spiegler; Eric Bouffet; Mark L Greenberg; James T Rutka; Donald J Mabbott
Journal:  J Clin Oncol       Date:  2004-02-15       Impact factor: 44.544

9.  Hydrocephalus as a possible additional contributor to cognitive outcome in survivors of pediatric medulloblastoma.

Authors:  Kristina K Hardy; Melanie J Bonner; Victoria W Willard; Melody Ann Watral; Sridharan Gururangan
Journal:  Psychooncology       Date:  2008-11       Impact factor: 3.894

10.  Working memory abilities among children treated for medulloblastoma: parent report and child performance.

Authors:  Sarah J Knight; Heather M Conklin; Shawna L Palmer; Jane E Schreiber; Carol L Armstrong; Dana Wallace; Melanie Bonner; Michelle A Swain; Karen D Evankovich; Donald J Mabbott; Robyn Boyle; Qinlei Huang; Hui Zhang; Vicki A Anderson; Amar Gajjar
Journal:  J Pediatr Psychol       Date:  2014-03-12
View more
  7 in total

1.  The posterior fossa syndrome questionnaire: using science to inform practice.

Authors:  Molly E Wickenhauser; Raja B Khan; Darcy Raches; Jason M Ashford; Kathryn M W Russell; Kristin Lyons; Giles W Robinson; Amar Gajjar; Paul Klimo; Heather M Conklin
Journal:  J Neurooncol       Date:  2022-04-05       Impact factor: 4.130

2.  Novel computerized neurocognitive test battery is sensitive to cancer-related cognitive deficits in survivors.

Authors:  Alexandra M Gaynor; Anam Ahsan; Duane Jung; Elizabeth Schofield; Yuelin Li; Elizabeth Ryan; Tim A Ahles; James C Root
Journal:  J Cancer Surviv       Date:  2022-08-08       Impact factor: 4.062

3.  An Integrated Analysis of Clinical, Genomic, and Imaging Features Reveals Predictors of Neurocognitive Outcomes in a Longitudinal Cohort of Pediatric Cancer Survivors, Enriched with CNS Tumors (Rad ART Pro).

Authors:  Cassie Kline; Schuyler Stoller; Lennox Byer; David Samuel; Janine M Lupo; Melanie A Morrison; Andreas M Rauschecker; Pierre Nedelec; Walter Faig; Dena B Dubal; Heather J Fullerton; Sabine Mueller
Journal:  Front Oncol       Date:  2022-06-23       Impact factor: 5.738

4.  Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma.

Authors:  Soumen Khatua; Laurence J N Cooper; David I Sandberg; Leena Ketonen; Jason M Johnson; Michael E Rytting; Diane D Liu; Heather Meador; Prashant Trikha; Robin J Nakkula; Gregory K Behbehani; Dristhi Ragoonanan; Sumit Gupta; Aikaterini Kotrotsou; Tagwa Idris; Elizabeth J Shpall; Katy Rezvani; Rivka Colen; Wafik Zaky; Dean A Lee; Vidya Gopalakrishnan
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 12.300

5.  Effect of sensorineural hearing loss on neurocognitive and adaptive functioning in survivors of pediatric embryonal brain tumor.

Authors:  Andrew M Heitzer; Alexandra M Villagran; Kimberly Raghubar; Austin L Brown; Miranda L Camet; M Douglas Ris; Jenny H Hanning; M Fatih Okcu; Arnold C Paulino; Murali Chintagumpala; Lisa S Kahalley
Journal:  J Neurooncol       Date:  2019-11-28       Impact factor: 4.130

Review 6.  Assessment and Monitoring of Neurocognitive Function in Pediatric Cancer.

Authors:  Lisa M Jacola; Marita Partanen; Jurgen Lemiere; Melissa M Hudson; Sophie Thomas
Journal:  J Clin Oncol       Date:  2021-04-22       Impact factor: 50.717

7.  Rate of radiation-induced microbleed formation on 7T MRI relates to cognitive impairment in young patients treated with radiation therapy for a brain tumor.

Authors:  Melanie A Morrison; Sabine Mueller; Erin Felton; Angela Jakary; Schuyler Stoller; Sivakami Avadiappan; Justin Yuan; Annette M Molinaro; Steve Braunstein; Anu Banerjee; Christopher P Hess; Janine M Lupo
Journal:  Radiother Oncol       Date:  2020-09-20       Impact factor: 6.280

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.